We have located links that may give you full text access.
[Non-alcoholic fatty liver disease (NAFLD)].
Recenti Progressi in Medicina 2016 July
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in adults and in the pediatric population of the western world; in a substantial proportion of subjects it takes on the characteristics of non-alcoholic steatohepatitis (NASH). The clinical significance of NAFLD is motivated by epidemiological data and its impact on liver-related morbidity and mortality on one hand and on the cardiovascular one on the other. The presence and extent of fibrosis on liver biopsy is the most relevant feature in predicting liver mortality, but the concept that the "simple steatosis" is benign has been recently questioned, especially in the presence of type 2 diabetes. Because the diagnosis of NASH is made by liver biopsy, the efforts of the scientific community are currently oriented to the search of non-invasive biomarkers of liver injury applicable on a large scale and of genetic polymorphisms associated to NASH in order to properly address the screening programs, follow-up and therapeutic attempts. Next to the therapy directed to the treatment of concomitant metabolic disorders, new drugs are being evaluated in clinical trials having as target the histologic resolution of NASH and regression of fibrosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app